nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—ABCB1—Methylprednisolone—multiple sclerosis	0.043	0.0957	CbGbCtD
Lapatinib—CYP3A4—Fingolimod—multiple sclerosis	0.0399	0.089	CbGbCtD
Lapatinib—CYP2C19—Prednisone—multiple sclerosis	0.0323	0.0718	CbGbCtD
Lapatinib—ABCB1—Mitoxantrone—multiple sclerosis	0.0313	0.0698	CbGbCtD
Lapatinib—ABCB1—Betamethasone—multiple sclerosis	0.0279	0.0622	CbGbCtD
Lapatinib—ABCB1—Prednisolone—multiple sclerosis	0.0276	0.0614	CbGbCtD
Lapatinib—ABCB1—Prednisone—multiple sclerosis	0.026	0.058	CbGbCtD
Lapatinib—CYP3A4—Methylprednisolone—multiple sclerosis	0.0257	0.0573	CbGbCtD
Lapatinib—CYP3A5—Dexamethasone—multiple sclerosis	0.025	0.0556	CbGbCtD
Lapatinib—CYP2C8—Dexamethasone—multiple sclerosis	0.024	0.0535	CbGbCtD
Lapatinib—CYP2C19—Dexamethasone—multiple sclerosis	0.0201	0.0448	CbGbCtD
Lapatinib—CYP3A4—Triamcinolone—multiple sclerosis	0.0195	0.0434	CbGbCtD
Lapatinib—CYP3A4—Mitoxantrone—multiple sclerosis	0.0188	0.0418	CbGbCtD
Lapatinib—CYP3A4—Betamethasone—multiple sclerosis	0.0167	0.0373	CbGbCtD
Lapatinib—CYP3A4—Prednisolone—multiple sclerosis	0.0165	0.0368	CbGbCtD
Lapatinib—ABCB1—Dexamethasone—multiple sclerosis	0.0162	0.0362	CbGbCtD
Lapatinib—CYP3A4—Prednisone—multiple sclerosis	0.0156	0.0347	CbGbCtD
Lapatinib—ABCB1—Methotrexate—multiple sclerosis	0.0131	0.0291	CbGbCtD
Lapatinib—CYP3A4—Dexamethasone—multiple sclerosis	0.00973	0.0217	CbGbCtD
Lapatinib—ERBB4—brainstem—multiple sclerosis	0.0041	0.0476	CbGeAlD
Lapatinib—TAP1—medulla oblongata—multiple sclerosis	0.00391	0.0455	CbGeAlD
Lapatinib—PIK3C2B—medulla oblongata—multiple sclerosis	0.00367	0.0427	CbGeAlD
Lapatinib—TAP1—midbrain—multiple sclerosis	0.00358	0.0416	CbGeAlD
Lapatinib—TAP1—spinal cord—multiple sclerosis	0.00349	0.0405	CbGeAlD
Lapatinib—PIK3C2B—midbrain—multiple sclerosis	0.00336	0.039	CbGeAlD
Lapatinib—PIK3C2B—spinal cord—multiple sclerosis	0.00328	0.0381	CbGeAlD
Lapatinib—ERBB4—medulla oblongata—multiple sclerosis	0.00286	0.0332	CbGeAlD
Lapatinib—TAP1—cerebellum—multiple sclerosis	0.00277	0.0321	CbGeAlD
Lapatinib—PIK3C2B—nervous system—multiple sclerosis	0.00276	0.0321	CbGeAlD
Lapatinib—PI4KB—medulla oblongata—multiple sclerosis	0.00268	0.0311	CbGeAlD
Lapatinib—PIK3C2B—central nervous system—multiple sclerosis	0.00266	0.0309	CbGeAlD
Lapatinib—ERBB4—midbrain—multiple sclerosis	0.00261	0.0303	CbGeAlD
Lapatinib—PIK3C2B—cerebellum—multiple sclerosis	0.0026	0.0302	CbGeAlD
Lapatinib—ERBB4—spinal cord—multiple sclerosis	0.00255	0.0296	CbGeAlD
Lapatinib—PI4KB—midbrain—multiple sclerosis	0.00245	0.0284	CbGeAlD
Lapatinib—PI4KB—spinal cord—multiple sclerosis	0.00239	0.0277	CbGeAlD
Lapatinib—TAP1—brain—multiple sclerosis	0.00225	0.0261	CbGeAlD
Lapatinib—ERBB2—nervous system—multiple sclerosis	0.00215	0.0249	CbGeAlD
Lapatinib—ERBB4—nervous system—multiple sclerosis	0.00215	0.0249	CbGeAlD
Lapatinib—PIK3C2B—brain—multiple sclerosis	0.00211	0.0245	CbGeAlD
Lapatinib—ERBB2—central nervous system—multiple sclerosis	0.00207	0.024	CbGeAlD
Lapatinib—ERBB4—central nervous system—multiple sclerosis	0.00207	0.024	CbGeAlD
Lapatinib—ERBB2—cerebellum—multiple sclerosis	0.00202	0.0235	CbGeAlD
Lapatinib—ERBB4—cerebellum—multiple sclerosis	0.00202	0.0235	CbGeAlD
Lapatinib—PI4KB—nervous system—multiple sclerosis	0.00201	0.0234	CbGeAlD
Lapatinib—PI4KB—central nervous system—multiple sclerosis	0.00194	0.0225	CbGeAlD
Lapatinib—PI4KB—cerebellum—multiple sclerosis	0.00189	0.022	CbGeAlD
Lapatinib—EGFR—cerebellum—multiple sclerosis	0.00171	0.0199	CbGeAlD
Lapatinib—ERBB2—brain—multiple sclerosis	0.00164	0.0191	CbGeAlD
Lapatinib—ERBB4—brain—multiple sclerosis	0.00164	0.0191	CbGeAlD
Lapatinib—PI4KB—brain—multiple sclerosis	0.00154	0.0179	CbGeAlD
Lapatinib—EGFR—brain—multiple sclerosis	0.00139	0.0162	CbGeAlD
Lapatinib—PIK3C2B—Clofarabine—Cladribine—multiple sclerosis	0.00093	0.115	CbGdCrCtD
Lapatinib—PIK3C2B—Exemestane—Methylprednisolone—multiple sclerosis	0.000653	0.0808	CbGdCrCtD
Lapatinib—PIK3C2B—Exemestane—Prednisone—multiple sclerosis	0.000596	0.0738	CbGdCrCtD
Lapatinib—PIK3C2B—Exemestane—Prednisolone—multiple sclerosis	0.000582	0.072	CbGdCrCtD
Lapatinib—PIK3C2B—Azacitidine—Cladribine—multiple sclerosis	0.000567	0.0702	CbGdCrCtD
Lapatinib—ERBB2—Exemestane—Methylprednisolone—multiple sclerosis	0.000538	0.0666	CbGdCrCtD
Lapatinib—Decreased appetite—Cladribine—multiple sclerosis	0.000534	0.0025	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.00053	0.00248	CcSEcCtD
Lapatinib—Fatigue—Cladribine—multiple sclerosis	0.000529	0.00248	CcSEcCtD
Lapatinib—Constipation—Cladribine—multiple sclerosis	0.000525	0.00246	CcSEcCtD
Lapatinib—Arthralgia—Azathioprine—multiple sclerosis	0.000521	0.00244	CcSEcCtD
Lapatinib—Myalgia—Azathioprine—multiple sclerosis	0.000521	0.00244	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000517	0.00242	CcSEcCtD
Lapatinib—ABCB1—retina—multiple sclerosis	0.000515	0.00598	CbGeAlD
Lapatinib—Dry skin—Dexamethasone—multiple sclerosis	0.000515	0.00241	CcSEcCtD
Lapatinib—Dry skin—Betamethasone—multiple sclerosis	0.000515	0.00241	CcSEcCtD
Lapatinib—Neuropathy peripheral—Prednisolone—multiple sclerosis	0.000509	0.00238	CcSEcCtD
Lapatinib—Gastrointestinal pain—Cladribine—multiple sclerosis	0.000502	0.00235	CcSEcCtD
Lapatinib—Alopecia—Mitoxantrone—multiple sclerosis	0.000502	0.00235	CcSEcCtD
Lapatinib—Cardiac failure—Prednisone—multiple sclerosis	0.000502	0.00235	CcSEcCtD
Lapatinib—Infection—Azathioprine—multiple sclerosis	0.000496	0.00232	CcSEcCtD
Lapatinib—ERBB2—Exemestane—Prednisone—multiple sclerosis	0.000491	0.0607	CbGdCrCtD
Lapatinib—Abdominal pain—Cladribine—multiple sclerosis	0.000485	0.00227	CcSEcCtD
Lapatinib—Skin disorder—Azathioprine—multiple sclerosis	0.000485	0.00227	CcSEcCtD
Lapatinib—ERBB2—Exemestane—Prednisolone—multiple sclerosis	0.000479	0.0593	CbGdCrCtD
Lapatinib—Back pain—Mitoxantrone—multiple sclerosis	0.000478	0.00224	CcSEcCtD
Lapatinib—Infestation NOS—Methylprednisolone—multiple sclerosis	0.000476	0.00223	CcSEcCtD
Lapatinib—Infestation—Methylprednisolone—multiple sclerosis	0.000476	0.00223	CcSEcCtD
Lapatinib—Neuropathy peripheral—Triamcinolone—multiple sclerosis	0.000468	0.00219	CcSEcCtD
Lapatinib—Neuropathy peripheral—Methylprednisolone—multiple sclerosis	0.000467	0.00218	CcSEcCtD
Lapatinib—Anaemia—Mitoxantrone—multiple sclerosis	0.000457	0.00214	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Azathioprine—multiple sclerosis	0.000455	0.00213	CcSEcCtD
Lapatinib—Hypersensitivity—Cladribine—multiple sclerosis	0.000452	0.00212	CcSEcCtD
Lapatinib—Epistaxis—Triamcinolone—multiple sclerosis	0.00045	0.00211	CcSEcCtD
Lapatinib—Dry skin—Prednisone—multiple sclerosis	0.000449	0.0021	CcSEcCtD
Lapatinib—CYP2C8—brain—multiple sclerosis	0.000446	0.00518	CbGeAlD
Lapatinib—Renal failure acute—Methotrexate—multiple sclerosis	0.000443	0.00207	CcSEcCtD
Lapatinib—Leukopenia—Mitoxantrone—multiple sclerosis	0.000443	0.00207	CcSEcCtD
Lapatinib—Asthenia—Cladribine—multiple sclerosis	0.00044	0.00206	CcSEcCtD
Lapatinib—Pruritus—Cladribine—multiple sclerosis	0.000434	0.00203	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Prednisone—multiple sclerosis	0.000432	0.00202	CcSEcCtD
Lapatinib—Cough—Mitoxantrone—multiple sclerosis	0.000431	0.00202	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000431	0.00202	CcSEcCtD
Lapatinib—Neuropathy peripheral—Dexamethasone—multiple sclerosis	0.000425	0.00199	CcSEcCtD
Lapatinib—Neuropathy peripheral—Betamethasone—multiple sclerosis	0.000425	0.00199	CcSEcCtD
Lapatinib—Myalgia—Mitoxantrone—multiple sclerosis	0.000421	0.00197	CcSEcCtD
Lapatinib—Arthralgia—Mitoxantrone—multiple sclerosis	0.000421	0.00197	CcSEcCtD
Lapatinib—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.00042	0.00197	CcSEcCtD
Lapatinib—Diarrhoea—Cladribine—multiple sclerosis	0.00042	0.00196	CcSEcCtD
Lapatinib—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000408	0.00191	CcSEcCtD
Lapatinib—Anaphylactic shock—Mitoxantrone—multiple sclerosis	0.000404	0.00189	CcSEcCtD
Lapatinib—Infection—Mitoxantrone—multiple sclerosis	0.000401	0.00188	CcSEcCtD
Lapatinib—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000397	0.00186	CcSEcCtD
Lapatinib—Neutropenia—Prednisone—multiple sclerosis	0.000396	0.00185	CcSEcCtD
Lapatinib—CYP3A4—nervous system—multiple sclerosis	0.000395	0.00459	CbGeAlD
Lapatinib—Abdominal pain—Azathioprine—multiple sclerosis	0.000395	0.00185	CcSEcCtD
Lapatinib—Skin disorder—Mitoxantrone—multiple sclerosis	0.000392	0.00183	CcSEcCtD
Lapatinib—Vomiting—Cladribine—multiple sclerosis	0.00039	0.00183	CcSEcCtD
Lapatinib—Angiopathy—Methylprednisolone—multiple sclerosis	0.000388	0.00181	CcSEcCtD
Lapatinib—Rash—Cladribine—multiple sclerosis	0.000387	0.00181	CcSEcCtD
Lapatinib—Dermatitis—Cladribine—multiple sclerosis	0.000387	0.00181	CcSEcCtD
Lapatinib—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000386	0.00181	CcSEcCtD
Lapatinib—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000385	0.0018	CcSEcCtD
Lapatinib—Anorexia—Mitoxantrone—multiple sclerosis	0.000385	0.0018	CcSEcCtD
Lapatinib—Headache—Cladribine—multiple sclerosis	0.000385	0.0018	CcSEcCtD
Lapatinib—CYP3A4—central nervous system—multiple sclerosis	0.000381	0.00442	CbGeAlD
Lapatinib—Mental disorder—Methylprednisolone—multiple sclerosis	0.000375	0.00175	CcSEcCtD
Lapatinib—ABCB1—medulla oblongata—multiple sclerosis	0.000372	0.00432	CbGeAlD
Lapatinib—Malnutrition—Methylprednisolone—multiple sclerosis	0.000372	0.00174	CcSEcCtD
Lapatinib—Neuropathy peripheral—Prednisone—multiple sclerosis	0.00037	0.00173	CcSEcCtD
Lapatinib—Hypersensitivity—Azathioprine—multiple sclerosis	0.000368	0.00172	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000368	0.00172	CcSEcCtD
Lapatinib—Nausea—Cladribine—multiple sclerosis	0.000365	0.00171	CcSEcCtD
Lapatinib—Back pain—Triamcinolone—multiple sclerosis	0.000361	0.00169	CcSEcCtD
Lapatinib—Dyspnoea—Mitoxantrone—multiple sclerosis	0.00036	0.00168	CcSEcCtD
Lapatinib—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000355	0.00166	CcSEcCtD
Lapatinib—Angiopathy—Betamethasone—multiple sclerosis	0.000353	0.00165	CcSEcCtD
Lapatinib—Angiopathy—Dexamethasone—multiple sclerosis	0.000353	0.00165	CcSEcCtD
Lapatinib—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000351	0.00164	CcSEcCtD
Lapatinib—Fatigue—Mitoxantrone—multiple sclerosis	0.000348	0.00163	CcSEcCtD
Lapatinib—Constipation—Mitoxantrone—multiple sclerosis	0.000345	0.00161	CcSEcCtD
Lapatinib—Alopecia—Dexamethasone—multiple sclerosis	0.000344	0.00161	CcSEcCtD
Lapatinib—Alopecia—Betamethasone—multiple sclerosis	0.000344	0.00161	CcSEcCtD
Lapatinib—Diarrhoea—Azathioprine—multiple sclerosis	0.000342	0.0016	CcSEcCtD
Lapatinib—ABCB1—midbrain—multiple sclerosis	0.00034	0.00395	CbGeAlD
Lapatinib—Connective tissue disorder—Prednisone—multiple sclerosis	0.000333	0.00156	CcSEcCtD
Lapatinib—ABCB1—spinal cord—multiple sclerosis	0.000332	0.00386	CbGeAlD
Lapatinib—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000331	0.00155	CcSEcCtD
Lapatinib—Neutropenia—Methotrexate—multiple sclerosis	0.000331	0.00155	CcSEcCtD
Lapatinib—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.00033	0.00154	CcSEcCtD
Lapatinib—Cough—Triamcinolone—multiple sclerosis	0.000326	0.00152	CcSEcCtD
Lapatinib—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000319	0.00149	CcSEcCtD
Lapatinib—Myalgia—Triamcinolone—multiple sclerosis	0.000318	0.00149	CcSEcCtD
Lapatinib—Vomiting—Azathioprine—multiple sclerosis	0.000317	0.00148	CcSEcCtD
Lapatinib—Pneumonia—Methotrexate—multiple sclerosis	0.000317	0.00148	CcSEcCtD
Lapatinib—Arthralgia—Methylprednisolone—multiple sclerosis	0.000317	0.00148	CcSEcCtD
Lapatinib—Myalgia—Methylprednisolone—multiple sclerosis	0.000317	0.00148	CcSEcCtD
Lapatinib—Infestation—Methotrexate—multiple sclerosis	0.000315	0.00147	CcSEcCtD
Lapatinib—Infestation NOS—Methotrexate—multiple sclerosis	0.000315	0.00147	CcSEcCtD
Lapatinib—Rash—Azathioprine—multiple sclerosis	0.000315	0.00147	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000315	0.00147	CcSEcCtD
Lapatinib—Dermatitis—Azathioprine—multiple sclerosis	0.000314	0.00147	CcSEcCtD
Lapatinib—Headache—Azathioprine—multiple sclerosis	0.000313	0.00146	CcSEcCtD
Lapatinib—Stomatitis—Methotrexate—multiple sclerosis	0.000307	0.00144	CcSEcCtD
Lapatinib—Angiopathy—Prednisone—multiple sclerosis	0.000307	0.00144	CcSEcCtD
Lapatinib—Immune system disorder—Prednisone—multiple sclerosis	0.000306	0.00143	CcSEcCtD
Lapatinib—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000304	0.00142	CcSEcCtD
Lapatinib—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000304	0.00142	CcSEcCtD
Lapatinib—Infection—Triamcinolone—multiple sclerosis	0.000302	0.00141	CcSEcCtD
Lapatinib—Infection—Methylprednisolone—multiple sclerosis	0.000302	0.00141	CcSEcCtD
Lapatinib—Insomnia—Prednisolone—multiple sclerosis	0.000299	0.0014	CcSEcCtD
Lapatinib—Alopecia—Prednisone—multiple sclerosis	0.000299	0.0014	CcSEcCtD
Lapatinib—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000298	0.00139	CcSEcCtD
Lapatinib—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000298	0.00139	CcSEcCtD
Lapatinib—Epistaxis—Methotrexate—multiple sclerosis	0.000297	0.00139	CcSEcCtD
Lapatinib—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000297	0.00139	CcSEcCtD
Lapatinib—Mental disorder—Prednisone—multiple sclerosis	0.000297	0.00139	CcSEcCtD
Lapatinib—Nausea—Azathioprine—multiple sclerosis	0.000296	0.00139	CcSEcCtD
Lapatinib—Skin disorder—Methylprednisolone—multiple sclerosis	0.000295	0.00138	CcSEcCtD
Lapatinib—Malnutrition—Prednisone—multiple sclerosis	0.000295	0.00138	CcSEcCtD
Lapatinib—ERBB2—Triamcinolone—Methylprednisolone—multiple sclerosis	0.000293	0.0363	CbGdCrCtD
Lapatinib—Asthenia—Mitoxantrone—multiple sclerosis	0.00029	0.00135	CcSEcCtD
Lapatinib—ERBB2—Triamcinolone—Dexamethasone—multiple sclerosis	0.000288	0.0357	CbGdCrCtD
Lapatinib—ERBB2—Triamcinolone—Betamethasone—multiple sclerosis	0.000288	0.0357	CbGdCrCtD
Lapatinib—Myalgia—Betamethasone—multiple sclerosis	0.000288	0.00135	CcSEcCtD
Lapatinib—Myalgia—Dexamethasone—multiple sclerosis	0.000288	0.00135	CcSEcCtD
Lapatinib—ABCB1—nervous system—multiple sclerosis	0.00028	0.00325	CbGeAlD
Lapatinib—ERBB2—Desoximetasone—Methylprednisolone—multiple sclerosis	0.000278	0.0344	CbGdCrCtD
Lapatinib—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000277	0.0013	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000277	0.00129	CcSEcCtD
Lapatinib—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000276	0.00129	CcSEcCtD
Lapatinib—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000276	0.00129	CcSEcCtD
Lapatinib—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000276	0.00129	CcSEcCtD
Lapatinib—Insomnia—Triamcinolone—multiple sclerosis	0.000275	0.00129	CcSEcCtD
Lapatinib—Insomnia—Methylprednisolone—multiple sclerosis	0.000275	0.00129	CcSEcCtD
Lapatinib—Infection—Dexamethasone—multiple sclerosis	0.000274	0.00128	CcSEcCtD
Lapatinib—Infection—Betamethasone—multiple sclerosis	0.000274	0.00128	CcSEcCtD
Lapatinib—ERBB2—Desoximetasone—Betamethasone—multiple sclerosis	0.000274	0.0339	CbGdCrCtD
Lapatinib—ERBB2—Desoximetasone—Dexamethasone—multiple sclerosis	0.000274	0.0339	CbGdCrCtD
Lapatinib—Anaemia—Prednisone—multiple sclerosis	0.000272	0.00127	CcSEcCtD
Lapatinib—Dyspnoea—Triamcinolone—multiple sclerosis	0.000271	0.00127	CcSEcCtD
Lapatinib—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000271	0.00127	CcSEcCtD
Lapatinib—Nervous system disorder—Betamethasone—multiple sclerosis	0.000271	0.00127	CcSEcCtD
Lapatinib—ABCB1—central nervous system—multiple sclerosis	0.000269	0.00313	CbGeAlD
Lapatinib—Dyspepsia—Triamcinolone—multiple sclerosis	0.000268	0.00125	CcSEcCtD
Lapatinib—ERBB2—Desoximetasone—Triamcinolone—multiple sclerosis	0.000267	0.0331	CbGdCrCtD
Lapatinib—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000267	0.00125	CcSEcCtD
Lapatinib—ERBB2—Triamcinolone—Prednisone—multiple sclerosis	0.000267	0.0331	CbGdCrCtD
Lapatinib—Anorexia—Dexamethasone—multiple sclerosis	0.000263	0.00123	CcSEcCtD
Lapatinib—Anorexia—Betamethasone—multiple sclerosis	0.000263	0.00123	CcSEcCtD
Lapatinib—ABCB1—cerebellum—multiple sclerosis	0.000263	0.00306	CbGeAlD
Lapatinib—Cardiac disorder—Methotrexate—multiple sclerosis	0.000263	0.00123	CcSEcCtD
Lapatinib—Fatigue—Triamcinolone—multiple sclerosis	0.000262	0.00123	CcSEcCtD
Lapatinib—Fatigue—Methylprednisolone—multiple sclerosis	0.000262	0.00122	CcSEcCtD
Lapatinib—ERBB2—Triamcinolone—Prednisolone—multiple sclerosis	0.000261	0.0323	CbGdCrCtD
Lapatinib—Angiopathy—Methotrexate—multiple sclerosis	0.000257	0.0012	CcSEcCtD
Lapatinib—Vomiting—Mitoxantrone—multiple sclerosis	0.000257	0.0012	CcSEcCtD
Lapatinib—Immune system disorder—Methotrexate—multiple sclerosis	0.000256	0.0012	CcSEcCtD
Lapatinib—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000255	0.00119	CcSEcCtD
Lapatinib—Rash—Mitoxantrone—multiple sclerosis	0.000254	0.00119	CcSEcCtD
Lapatinib—Dermatitis—Mitoxantrone—multiple sclerosis	0.000254	0.00119	CcSEcCtD
Lapatinib—ERBB2—Desoximetasone—Prednisone—multiple sclerosis	0.000254	0.0314	CbGdCrCtD
Lapatinib—Headache—Mitoxantrone—multiple sclerosis	0.000253	0.00118	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000252	0.00118	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000252	0.00118	CcSEcCtD
Lapatinib—PIK3C2B—Danazol—Prednisone—multiple sclerosis	0.000251	0.0311	CbGdCrCtD
Lapatinib—Arthralgia—Prednisone—multiple sclerosis	0.000251	0.00117	CcSEcCtD
Lapatinib—Myalgia—Prednisone—multiple sclerosis	0.000251	0.00117	CcSEcCtD
Lapatinib—Alopecia—Methotrexate—multiple sclerosis	0.00025	0.00117	CcSEcCtD
Lapatinib—Insomnia—Dexamethasone—multiple sclerosis	0.00025	0.00117	CcSEcCtD
Lapatinib—Insomnia—Betamethasone—multiple sclerosis	0.00025	0.00117	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000249	0.00117	CcSEcCtD
Lapatinib—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000248	0.00116	CcSEcCtD
Lapatinib—Mental disorder—Methotrexate—multiple sclerosis	0.000248	0.00116	CcSEcCtD
Lapatinib—ERBB2—Desoximetasone—Prednisolone—multiple sclerosis	0.000248	0.0307	CbGdCrCtD
Lapatinib—Malnutrition—Methotrexate—multiple sclerosis	0.000246	0.00115	CcSEcCtD
Lapatinib—Hypersensitivity—Prednisolone—multiple sclerosis	0.000244	0.00114	CcSEcCtD
Lapatinib—Dyspepsia—Betamethasone—multiple sclerosis	0.000243	0.00114	CcSEcCtD
Lapatinib—Dyspepsia—Dexamethasone—multiple sclerosis	0.000243	0.00114	CcSEcCtD
Lapatinib—Anaphylactic shock—Prednisone—multiple sclerosis	0.000241	0.00113	CcSEcCtD
Lapatinib—Abdominal pain—Methylprednisolone—multiple sclerosis	0.00024	0.00112	CcSEcCtD
Lapatinib—Decreased appetite—Betamethasone—multiple sclerosis	0.00024	0.00112	CcSEcCtD
Lapatinib—Decreased appetite—Dexamethasone—multiple sclerosis	0.00024	0.00112	CcSEcCtD
Lapatinib—Nausea—Mitoxantrone—multiple sclerosis	0.00024	0.00112	CcSEcCtD
Lapatinib—Infection—Prednisone—multiple sclerosis	0.000239	0.00112	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000238	0.00112	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000238	0.00112	CcSEcCtD
Lapatinib—Back pain—Methotrexate—multiple sclerosis	0.000238	0.00111	CcSEcCtD
Lapatinib—Fatigue—Betamethasone—multiple sclerosis	0.000238	0.00111	CcSEcCtD
Lapatinib—Fatigue—Dexamethasone—multiple sclerosis	0.000238	0.00111	CcSEcCtD
Lapatinib—Nervous system disorder—Prednisone—multiple sclerosis	0.000236	0.0011	CcSEcCtD
Lapatinib—Skin disorder—Prednisone—multiple sclerosis	0.000234	0.00109	CcSEcCtD
Lapatinib—Anorexia—Prednisone—multiple sclerosis	0.000229	0.00107	CcSEcCtD
Lapatinib—Anaemia—Methotrexate—multiple sclerosis	0.000228	0.00106	CcSEcCtD
Lapatinib—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000226	0.00106	CcSEcCtD
Lapatinib—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000226	0.00106	CcSEcCtD
Lapatinib—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000224	0.00105	CcSEcCtD
Lapatinib—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000224	0.00105	CcSEcCtD
Lapatinib—Leukopenia—Methotrexate—multiple sclerosis	0.000221	0.00103	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000219	0.00103	CcSEcCtD
Lapatinib—Asthenia—Triamcinolone—multiple sclerosis	0.000218	0.00102	CcSEcCtD
Lapatinib—Abdominal pain—Betamethasone—multiple sclerosis	0.000218	0.00102	CcSEcCtD
Lapatinib—Abdominal pain—Dexamethasone—multiple sclerosis	0.000218	0.00102	CcSEcCtD
Lapatinib—Asthenia—Methylprednisolone—multiple sclerosis	0.000218	0.00102	CcSEcCtD
Lapatinib—Insomnia—Prednisone—multiple sclerosis	0.000218	0.00102	CcSEcCtD
Lapatinib—Pruritus—Triamcinolone—multiple sclerosis	0.000215	0.00101	CcSEcCtD
Lapatinib—Cough—Methotrexate—multiple sclerosis	0.000215	0.00101	CcSEcCtD
Lapatinib—Pruritus—Methylprednisolone—multiple sclerosis	0.000215	0.00101	CcSEcCtD
Lapatinib—ABCB1—brain—multiple sclerosis	0.000214	0.00248	CbGeAlD
Lapatinib—Dyspepsia—Prednisone—multiple sclerosis	0.000212	0.00099	CcSEcCtD
Lapatinib—Arthralgia—Methotrexate—multiple sclerosis	0.00021	0.000981	CcSEcCtD
Lapatinib—Myalgia—Methotrexate—multiple sclerosis	0.00021	0.000981	CcSEcCtD
Lapatinib—Decreased appetite—Prednisone—multiple sclerosis	0.000209	0.000978	CcSEcCtD
Lapatinib—Rash—Prednisolone—multiple sclerosis	0.000209	0.000976	CcSEcCtD
Lapatinib—Dermatitis—Prednisolone—multiple sclerosis	0.000209	0.000975	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000208	0.000974	CcSEcCtD
Lapatinib—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000208	0.000972	CcSEcCtD
Lapatinib—Fatigue—Prednisone—multiple sclerosis	0.000207	0.00097	CcSEcCtD
Lapatinib—Headache—Prednisolone—multiple sclerosis	0.000207	0.00097	CcSEcCtD
Lapatinib—Constipation—Prednisone—multiple sclerosis	0.000206	0.000962	CcSEcCtD
Lapatinib—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000201	0.00094	CcSEcCtD
Lapatinib—Infection—Methotrexate—multiple sclerosis	0.0002	0.000934	CcSEcCtD
Lapatinib—Asthenia—Betamethasone—multiple sclerosis	0.000198	0.000927	CcSEcCtD
Lapatinib—Asthenia—Dexamethasone—multiple sclerosis	0.000198	0.000927	CcSEcCtD
Lapatinib—Nervous system disorder—Methotrexate—multiple sclerosis	0.000197	0.000922	CcSEcCtD
Lapatinib—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000197	0.00092	CcSEcCtD
Lapatinib—Nausea—Prednisolone—multiple sclerosis	0.000197	0.00092	CcSEcCtD
Lapatinib—Pruritus—Betamethasone—multiple sclerosis	0.000195	0.000914	CcSEcCtD
Lapatinib—Pruritus—Dexamethasone—multiple sclerosis	0.000195	0.000914	CcSEcCtD
Lapatinib—Skin disorder—Methotrexate—multiple sclerosis	0.000195	0.000913	CcSEcCtD
Lapatinib—Vomiting—Triamcinolone—multiple sclerosis	0.000194	0.000905	CcSEcCtD
Lapatinib—Vomiting—Methylprednisolone—multiple sclerosis	0.000193	0.000903	CcSEcCtD
Lapatinib—Rash—Triamcinolone—multiple sclerosis	0.000192	0.000898	CcSEcCtD
Lapatinib—Dermatitis—Triamcinolone—multiple sclerosis	0.000192	0.000897	CcSEcCtD
Lapatinib—Anorexia—Methotrexate—multiple sclerosis	0.000192	0.000896	CcSEcCtD
Lapatinib—Rash—Methylprednisolone—multiple sclerosis	0.000192	0.000896	CcSEcCtD
Lapatinib—Dermatitis—Methylprednisolone—multiple sclerosis	0.000191	0.000895	CcSEcCtD
Lapatinib—Headache—Triamcinolone—multiple sclerosis	0.000191	0.000892	CcSEcCtD
Lapatinib—Headache—Methylprednisolone—multiple sclerosis	0.00019	0.00089	CcSEcCtD
Lapatinib—Abdominal pain—Prednisone—multiple sclerosis	0.00019	0.000889	CcSEcCtD
Lapatinib—Diarrhoea—Dexamethasone—multiple sclerosis	0.000189	0.000884	CcSEcCtD
Lapatinib—Diarrhoea—Betamethasone—multiple sclerosis	0.000189	0.000884	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000183	0.000857	CcSEcCtD
Lapatinib—Insomnia—Methotrexate—multiple sclerosis	0.000182	0.000851	CcSEcCtD
Lapatinib—Nausea—Triamcinolone—multiple sclerosis	0.000181	0.000846	CcSEcCtD
Lapatinib—Nausea—Methylprednisolone—multiple sclerosis	0.00018	0.000844	CcSEcCtD
Lapatinib—Dyspnoea—Methotrexate—multiple sclerosis	0.000179	0.000838	CcSEcCtD
Lapatinib—Hypersensitivity—Prednisone—multiple sclerosis	0.000177	0.000829	CcSEcCtD
Lapatinib—Dyspepsia—Methotrexate—multiple sclerosis	0.000177	0.000828	CcSEcCtD
Lapatinib—Vomiting—Betamethasone—multiple sclerosis	0.000176	0.000822	CcSEcCtD
Lapatinib—Vomiting—Dexamethasone—multiple sclerosis	0.000176	0.000822	CcSEcCtD
Lapatinib—Decreased appetite—Methotrexate—multiple sclerosis	0.000175	0.000817	CcSEcCtD
Lapatinib—Rash—Dexamethasone—multiple sclerosis	0.000174	0.000815	CcSEcCtD
Lapatinib—Rash—Betamethasone—multiple sclerosis	0.000174	0.000815	CcSEcCtD
Lapatinib—Dermatitis—Betamethasone—multiple sclerosis	0.000174	0.000814	CcSEcCtD
Lapatinib—Dermatitis—Dexamethasone—multiple sclerosis	0.000174	0.000814	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000174	0.000812	CcSEcCtD
Lapatinib—Fatigue—Methotrexate—multiple sclerosis	0.000173	0.000811	CcSEcCtD
Lapatinib—Headache—Dexamethasone—multiple sclerosis	0.000173	0.000809	CcSEcCtD
Lapatinib—Headache—Betamethasone—multiple sclerosis	0.000173	0.000809	CcSEcCtD
Lapatinib—Asthenia—Prednisone—multiple sclerosis	0.000173	0.000807	CcSEcCtD
Lapatinib—Pruritus—Prednisone—multiple sclerosis	0.00017	0.000796	CcSEcCtD
Lapatinib—Diarrhoea—Prednisone—multiple sclerosis	0.000165	0.00077	CcSEcCtD
Lapatinib—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000164	0.000769	CcSEcCtD
Lapatinib—Nausea—Betamethasone—multiple sclerosis	0.000164	0.000767	CcSEcCtD
Lapatinib—Nausea—Dexamethasone—multiple sclerosis	0.000164	0.000767	CcSEcCtD
Lapatinib—Abdominal pain—Methotrexate—multiple sclerosis	0.000159	0.000743	CcSEcCtD
Lapatinib—Vomiting—Prednisone—multiple sclerosis	0.000153	0.000715	CcSEcCtD
Lapatinib—Rash—Prednisone—multiple sclerosis	0.000152	0.000709	CcSEcCtD
Lapatinib—Dermatitis—Prednisone—multiple sclerosis	0.000152	0.000709	CcSEcCtD
Lapatinib—Headache—Prednisone—multiple sclerosis	0.000151	0.000705	CcSEcCtD
Lapatinib—Hypersensitivity—Methotrexate—multiple sclerosis	0.000148	0.000693	CcSEcCtD
Lapatinib—Asthenia—Methotrexate—multiple sclerosis	0.000144	0.000675	CcSEcCtD
Lapatinib—Nausea—Prednisone—multiple sclerosis	0.000143	0.000668	CcSEcCtD
Lapatinib—Pruritus—Methotrexate—multiple sclerosis	0.000142	0.000665	CcSEcCtD
Lapatinib—Diarrhoea—Methotrexate—multiple sclerosis	0.000138	0.000643	CcSEcCtD
Lapatinib—Vomiting—Methotrexate—multiple sclerosis	0.000128	0.000598	CcSEcCtD
Lapatinib—Rash—Methotrexate—multiple sclerosis	0.000127	0.000593	CcSEcCtD
Lapatinib—Dermatitis—Methotrexate—multiple sclerosis	0.000127	0.000592	CcSEcCtD
Lapatinib—Headache—Methotrexate—multiple sclerosis	0.000126	0.000589	CcSEcCtD
Lapatinib—Nausea—Methotrexate—multiple sclerosis	0.000119	0.000559	CcSEcCtD
Lapatinib—ERBB4—Disease—APOE—multiple sclerosis	3.63e-05	0.000149	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—GPR65—multiple sclerosis	3.61e-05	0.000148	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—CD80—multiple sclerosis	3.6e-05	0.000148	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CXCL10—multiple sclerosis	3.6e-05	0.000148	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CCR2—multiple sclerosis	3.6e-05	0.000148	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB4—IL6—multiple sclerosis	3.59e-05	0.000148	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—TNF—multiple sclerosis	3.58e-05	0.000147	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—CD80—multiple sclerosis	3.55e-05	0.000146	CbGpPWpGaD
Lapatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	3.54e-05	0.000146	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.49e-05	0.000144	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—GPC5—multiple sclerosis	3.48e-05	0.000143	CbGpPWpGaD
Lapatinib—EGFR—Downstream signal transduction—IL6—multiple sclerosis	3.43e-05	0.000141	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR—IL6—multiple sclerosis	3.41e-05	0.00014	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—HLA-A—multiple sclerosis	3.4e-05	0.00014	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB2—IL6—multiple sclerosis	3.4e-05	0.00014	CbGpPWpGaD
Lapatinib—EGFR—DAP12 signaling—IL6—multiple sclerosis	3.38e-05	0.000139	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CD28—multiple sclerosis	3.35e-05	0.000138	CbGpPWpGaD
Lapatinib—ERBB2—Disease—CD80—multiple sclerosis	3.33e-05	0.000137	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—MAPK1—multiple sclerosis	3.33e-05	0.000137	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CNR1—multiple sclerosis	3.32e-05	0.000137	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCR1—multiple sclerosis	3.3e-05	0.000136	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CXCL13—multiple sclerosis	3.3e-05	0.000136	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	3.3e-05	0.000136	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	3.3e-05	0.000136	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CCR2—multiple sclerosis	3.29e-05	0.000135	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PTPRC—multiple sclerosis	3.29e-05	0.000135	CbGpPWpGaD
Lapatinib—ERBB4—Disease—CD80—multiple sclerosis	3.28e-05	0.000135	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—MAPK1—multiple sclerosis	3.28e-05	0.000135	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—TLR4—multiple sclerosis	3.24e-05	0.000133	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.22e-05	0.000133	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CD86—multiple sclerosis	3.19e-05	0.000131	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—multiple sclerosis	3.18e-05	0.000131	CbGpPWpGaD
Lapatinib—EGFR—DAP12 interactions—IL6—multiple sclerosis	3.18e-05	0.000131	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—IL6—multiple sclerosis	3.18e-05	0.000131	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HLA-DPB1—multiple sclerosis	3.18e-05	0.000131	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—MMP9—multiple sclerosis	3.16e-05	0.00013	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR—IL6—multiple sclerosis	3.15e-05	0.00013	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CD86—multiple sclerosis	3.15e-05	0.000129	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CCL5—multiple sclerosis	3.14e-05	0.000129	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—IL6—multiple sclerosis	3.12e-05	0.000128	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—HLA-DRB1—multiple sclerosis	3.11e-05	0.000128	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—IL6—multiple sclerosis	3.11e-05	0.000128	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—STAT3—multiple sclerosis	3.1e-05	0.000128	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CCL5—multiple sclerosis	3.1e-05	0.000127	CbGpPWpGaD
Lapatinib—EGFR—Disease—CD28—multiple sclerosis	3.09e-05	0.000127	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CD40—multiple sclerosis	3.06e-05	0.000126	CbGpPWpGaD
Lapatinib—EGFR—Immune System—ITGA4—multiple sclerosis	3.06e-05	0.000126	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—TYK2—multiple sclerosis	3.04e-05	0.000125	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IFNB1—multiple sclerosis	3.03e-05	0.000125	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GPC5—multiple sclerosis	3.02e-05	0.000124	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CTLA4—multiple sclerosis	3.01e-05	0.000124	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—TYK2—multiple sclerosis	3e-05	0.000123	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—CD80—multiple sclerosis	2.99e-05	0.000123	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CXCL10—multiple sclerosis	2.99e-05	0.000123	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—ICAM1—multiple sclerosis	2.98e-05	0.000123	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	2.94e-05	0.000121	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	2.94e-05	0.000121	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—SPP1—multiple sclerosis	2.91e-05	0.00012	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—IL6—multiple sclerosis	2.89e-05	0.000119	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—RRM1—multiple sclerosis	2.88e-05	0.000119	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.88e-05	0.000118	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—CD80—multiple sclerosis	2.87e-05	0.000118	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP27B1—multiple sclerosis	2.87e-05	0.000118	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP24A1—multiple sclerosis	2.87e-05	0.000118	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—SPP1—multiple sclerosis	2.87e-05	0.000118	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—TYK2—multiple sclerosis	2.86e-05	0.000118	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IFNG—multiple sclerosis	2.85e-05	0.000117	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CCR5—multiple sclerosis	2.83e-05	0.000117	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—MAPK1—multiple sclerosis	2.82e-05	0.000116	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—multiple sclerosis	2.82e-05	0.000116	CbGpPWpGaD
Lapatinib—ERBB2—Disease—TYK2—multiple sclerosis	2.81e-05	0.000116	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—IFNG—multiple sclerosis	2.81e-05	0.000115	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IL2RA—multiple sclerosis	2.79e-05	0.000115	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CCR5—multiple sclerosis	2.79e-05	0.000115	CbGpPWpGaD
Lapatinib—ERBB4—Disease—TYK2—multiple sclerosis	2.77e-05	0.000114	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—CD4—multiple sclerosis	2.75e-05	0.000113	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IL2RA—multiple sclerosis	2.75e-05	0.000113	CbGpPWpGaD
Lapatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	2.72e-05	0.000112	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—CD4—multiple sclerosis	2.71e-05	0.000112	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GPC5—multiple sclerosis	2.69e-05	0.000111	CbGpPWpGaD
Lapatinib—EGFR—Immune System—VCAM1—multiple sclerosis	2.66e-05	0.000109	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HLA-DQA1—multiple sclerosis	2.65e-05	0.000109	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GPC5—multiple sclerosis	2.63e-05	0.000108	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—APOE—multiple sclerosis	2.58e-05	0.000106	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CCL5—multiple sclerosis	2.57e-05	0.000106	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—IL6—multiple sclerosis	2.55e-05	0.000105	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—MAPK1—multiple sclerosis	2.55e-05	0.000105	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IL1B—multiple sclerosis	2.54e-05	0.000105	CbGpPWpGaD
Lapatinib—ERBB2—Disease—CD4—multiple sclerosis	2.54e-05	0.000105	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—APOE—multiple sclerosis	2.54e-05	0.000104	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IL2—multiple sclerosis	2.53e-05	0.000104	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—TYK2—multiple sclerosis	2.53e-05	0.000104	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—IL6—multiple sclerosis	2.52e-05	0.000104	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SRM—multiple sclerosis	2.51e-05	0.000103	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—IL1B—multiple sclerosis	2.5e-05	0.000103	CbGpPWpGaD
Lapatinib—ERBB4—Disease—CD4—multiple sclerosis	2.5e-05	0.000103	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—RRM1—multiple sclerosis	2.5e-05	0.000103	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—IL2—multiple sclerosis	2.49e-05	0.000103	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HLA-DQB1—multiple sclerosis	2.48e-05	0.000102	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CD86—multiple sclerosis	2.39e-05	9.83e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCL3—multiple sclerosis	2.35e-05	9.67e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CD40LG—multiple sclerosis	2.34e-05	9.64e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CD80—multiple sclerosis	2.33e-05	9.59e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Biological oxidations—POMC—multiple sclerosis	2.33e-05	9.58e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CCR5—multiple sclerosis	2.32e-05	9.54e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CD8A—multiple sclerosis	2.32e-05	9.53e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CD80—multiple sclerosis	2.3e-05	9.44e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—IL2RA—multiple sclerosis	2.28e-05	9.4e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—CD4—multiple sclerosis	2.28e-05	9.4e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PTGER4—multiple sclerosis	2.26e-05	9.31e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—MMP9—multiple sclerosis	2.25e-05	9.27e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—RRM1—multiple sclerosis	2.23e-05	9.18e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HLA-B—multiple sclerosis	2.23e-05	9.17e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PGR—multiple sclerosis	2.23e-05	9.17e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—POMC—multiple sclerosis	2.21e-05	9.11e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—CD86—multiple sclerosis	2.21e-05	9.07e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—CD4—multiple sclerosis	2.19e-05	9.02e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CXCR3—multiple sclerosis	2.18e-05	8.99e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—POMC—multiple sclerosis	2.18e-05	8.97e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—RRM1—multiple sclerosis	2.18e-05	8.96e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CCL2—multiple sclerosis	2.17e-05	8.91e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—IL6—multiple sclerosis	2.17e-05	8.91e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CD28—multiple sclerosis	2.16e-05	8.9e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CCL2—multiple sclerosis	2.13e-05	8.78e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—STAT3—multiple sclerosis	2.13e-05	8.77e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCR2—multiple sclerosis	2.13e-05	8.74e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—STAT3—multiple sclerosis	2.1e-05	8.63e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL2RA—multiple sclerosis	2.09e-05	8.59e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HLA-A—multiple sclerosis	2.06e-05	8.49e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	2.01e-05	8.26e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	2e-05	8.24e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—STAT3—multiple sclerosis	2e-05	8.24e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TYK2—multiple sclerosis	1.97e-05	8.09e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—STAT3—multiple sclerosis	1.97e-05	8.09e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.96e-05	8.08e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CNR1—multiple sclerosis	1.96e-05	8.07e-05	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—IL6—multiple sclerosis	1.96e-05	8.06e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—CCR5—multiple sclerosis	1.96e-05	8.05e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.94e-05	7.98e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TYK2—multiple sclerosis	1.94e-05	7.97e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—STAT3—multiple sclerosis	1.94e-05	7.97e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—MAPK1—multiple sclerosis	1.94e-05	7.97e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—MAPK1—multiple sclerosis	1.91e-05	7.85e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—HLA-A—multiple sclerosis	1.91e-05	7.84e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—TLR4—multiple sclerosis	1.89e-05	7.77e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HLA-DRB1—multiple sclerosis	1.89e-05	7.76e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.87e-05	7.7e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—TGFB1—multiple sclerosis	1.86e-05	7.64e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—MYC—multiple sclerosis	1.83e-05	7.52e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—TGFB1—multiple sclerosis	1.82e-05	7.5e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—MAPK1—multiple sclerosis	1.82e-05	7.49e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—POMC—multiple sclerosis	1.81e-05	7.46e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—ICAM1—multiple sclerosis	1.81e-05	7.45e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—MYC—multiple sclerosis	1.8e-05	7.41e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—TGFB1—multiple sclerosis	1.8e-05	7.39e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—MAPK1—multiple sclerosis	1.79e-05	7.36e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—APOE—multiple sclerosis	1.78e-05	7.32e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CCL2—multiple sclerosis	1.77e-05	7.29e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.77e-05	7.28e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.77e-05	7.28e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CXCL10—multiple sclerosis	1.77e-05	7.27e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—MAPK1—multiple sclerosis	1.76e-05	7.25e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CD80—multiple sclerosis	1.74e-05	7.17e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—TNF—multiple sclerosis	1.73e-05	7.13e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.73e-05	7.12e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.67e-05	6.85e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—BCHE—multiple sclerosis	1.66e-05	6.82e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IL2—multiple sclerosis	1.64e-05	6.73e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.62e-05	6.66e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IL2—multiple sclerosis	1.61e-05	6.63e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—TYK2—multiple sclerosis	1.61e-05	6.62e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—CD80—multiple sclerosis	1.61e-05	6.62e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—MAPK1—multiple sclerosis	1.61e-05	6.61e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MMP9—multiple sclerosis	1.55e-05	6.37e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CD86—multiple sclerosis	1.54e-05	6.35e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MMP9—multiple sclerosis	1.53e-05	6.28e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCL5—multiple sclerosis	1.52e-05	6.25e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.52e-05	6.25e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IL6—multiple sclerosis	1.49e-05	6.12e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.49e-05	6.12e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—TYK2—multiple sclerosis	1.47e-05	6.05e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—IL6—multiple sclerosis	1.47e-05	6.03e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—BCHE—multiple sclerosis	1.44e-05	5.9e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SPP1—multiple sclerosis	1.41e-05	5.79e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—IL6—multiple sclerosis	1.4e-05	5.75e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—STAT3—multiple sclerosis	1.38e-05	5.67e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IFNG—multiple sclerosis	1.38e-05	5.67e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—IL6—multiple sclerosis	1.37e-05	5.65e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCR5—multiple sclerosis	1.37e-05	5.63e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—TYK2—multiple sclerosis	1.36e-05	5.59e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—STAT3—multiple sclerosis	1.36e-05	5.58e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.36e-05	5.58e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—IL6—multiple sclerosis	1.35e-05	5.57e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL2RA—multiple sclerosis	1.35e-05	5.55e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.34e-05	5.52e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—IL2—multiple sclerosis	1.34e-05	5.51e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CD4—multiple sclerosis	1.33e-05	5.47e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—BCHE—multiple sclerosis	1.28e-05	5.27e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MYC—multiple sclerosis	1.28e-05	5.27e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TGFB1—multiple sclerosis	1.28e-05	5.25e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MYC—multiple sclerosis	1.26e-05	5.19e-05	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.26e-05	5.17e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TGFB1—multiple sclerosis	1.26e-05	5.17e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MAPK1—multiple sclerosis	1.25e-05	5.15e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—BCHE—multiple sclerosis	1.25e-05	5.14e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—APOE—multiple sclerosis	1.25e-05	5.13e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—IL6—multiple sclerosis	1.24e-05	5.08e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MAPK1—multiple sclerosis	1.23e-05	5.07e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL1B—multiple sclerosis	1.23e-05	5.05e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—CD4—multiple sclerosis	1.23e-05	5.05e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL2—multiple sclerosis	1.22e-05	5.04e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CD80—multiple sclerosis	1.13e-05	4.63e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—POMC—multiple sclerosis	1.07e-05	4.4e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCL2—multiple sclerosis	1.05e-05	4.31e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—STAT3—multiple sclerosis	1.03e-05	4.24e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—MAPK1—multiple sclerosis	1.02e-05	4.22e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—APOE—multiple sclerosis	9.97e-06	4.1e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IL6—multiple sclerosis	9.62e-06	3.96e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TYK2—multiple sclerosis	9.51e-06	3.91e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—STAT3—multiple sclerosis	9.51e-06	3.91e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IL6—multiple sclerosis	9.48e-06	3.9e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—MAPK1—multiple sclerosis	9.36e-06	3.85e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—MYC—multiple sclerosis	8.84e-06	3.64e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—TGFB1—multiple sclerosis	8.81e-06	3.63e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—MAPK1—multiple sclerosis	8.64e-06	3.56e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—APOE—multiple sclerosis	8.63e-06	3.55e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—POMC—multiple sclerosis	8.56e-06	3.52e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL2—multiple sclerosis	7.91e-06	3.26e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—IL6—multiple sclerosis	7.87e-06	3.24e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ALB—multiple sclerosis	7.81e-06	3.21e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—APOE—multiple sclerosis	7.71e-06	3.17e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—BCHE—multiple sclerosis	7.7e-06	3.17e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—APOE—multiple sclerosis	7.52e-06	3.09e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MMP9—multiple sclerosis	7.49e-06	3.08e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—POMC—multiple sclerosis	7.42e-06	3.05e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL6—multiple sclerosis	7.19e-06	2.96e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ALB—multiple sclerosis	6.76e-06	2.78e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—STAT3—multiple sclerosis	6.66e-06	2.74e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—IL6—multiple sclerosis	6.64e-06	2.73e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—POMC—multiple sclerosis	6.62e-06	2.72e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—POMC—multiple sclerosis	6.46e-06	2.66e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MYC—multiple sclerosis	6.19e-06	2.55e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TGFB1—multiple sclerosis	6.17e-06	2.54e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MAPK1—multiple sclerosis	6.05e-06	2.49e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ALB—multiple sclerosis	6.04e-06	2.48e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ALB—multiple sclerosis	5.89e-06	2.42e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL6—multiple sclerosis	4.65e-06	1.91e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—APOE—multiple sclerosis	4.63e-06	1.91e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—POMC—multiple sclerosis	3.98e-06	1.64e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ALB—multiple sclerosis	3.63e-06	1.49e-05	CbGpPWpGaD
